• 15329 Citations
  • 55 h-Index
19982019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Seock-Ah Im is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 51 Similar Profiles
Breast Neoplasms Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Stomach Neoplasms Medicine & Life Sciences
Survival Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Disease-Free Survival Medicine & Life Sciences
docetaxel Medicine & Life Sciences
gemcitabine Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1998 2019

  • 15329 Citations
  • 55 h-Index
  • 392 Article
  • 10 Review article
  • 4 Comment/debate
  • 1 Letter

Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial

Robson, M., Ruddy, K. J., Im, S-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Li, W., Tung, N., Armstrong, A., Delaloge, S., Bannister, W., Goessl, C., Degboe, A., Hettle, R. & Conte, P., 1 Oct 2019, In : European Journal of Cancer. 120, p. 20-30 11 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
Germ-Line Mutation
Breast Neoplasms
Drug Therapy
Physicians
Quality of Life

Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients

Kim, J. Y., Lee, E., Park, K., Jung, H. H., Park, W. Y., Lee, K-H., Sohn, J., Lee, K. S., Jung, K. H., Kim, J. H., Lee, K. H., Im, S-A. & Park, Y. H., 15 Sep 2019, In : International Journal of Cancer. 145, 6, p. 1669-1678 10 p.

Research output: Contribution to journalArticleResearchpeer-review

Phase II Clinical Trials
Biomarkers
Breast Neoplasms
Nucleotides
Disease-Free Survival

Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer

Luo, Y., Li, W., Jiang, Z., Zhang, Q., Wang, L., Mao, Y., Tjan-Heijnen, V. C. G., Im, S-A., McConnell, R., Bejarano, S., Fumagalli, D., Bines, J., Wang, B., Garg, A., Kirschbrown, W. P. & Xu, B., 1 Sep 2019, In : Anti-cancer drugs. 30, 8, p. 866-872 7 p.

Research output: Contribution to journalArticleResearchpeer-review

Pharmacokinetics
Breast Neoplasms
pertuzumab
Trastuzumab
Serum

Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage I–III breast cancer patients

Lee, D. W., Ryu, H. S., Jin, M. S., Lee, K. H., Suh, K. J., Youk, J., Kim, J. Y., Min, A., Lee, H. B., Moon, H. G., Kim, T. Y., Han, S-W., Oh, D-Y., Han, W., Park, I., Noh, D. & Im, S-A., 30 Jul 2019, In : British Journal of Cancer. 121, 3, p. 230-236 7 p.

Research output: Contribution to journalArticleResearchpeer-review

Breast Neoplasms
Recurrence
Proteins
Biomarkers
Tumor-Infiltrating Lymphocytes
1 Citation (Scopus)

Prognostic role of body mass index is different according to menopausal status and tumor subtype in breast cancer patients

Kim, J. Y., Lee, D. W., Lee, K-H., Min, A., Ryu, H. S., Lee, H-B., Moon, H. G., Kim, T-Y., Han, S-W., Oh, D-Y., Han, W., Park, I., Noh, D., Im, S-A. & Kim, S., 30 Jul 2019, In : Breast Cancer Research and Treatment. 176, 2, p. 453-460 8 p.

Research output: Contribution to journalArticleResearchpeer-review

Body Mass Index
Hormones
Breast Neoplasms
Thinness
Neoplasms